A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury

Drug repurposing has the advantage of identifying potential treatments on a shortened timescale. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high-content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Kost-Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Chamberlain, Brian T., Dvela-Levitt, Moran, Melanson, Michelle, Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Byrne, Patrick J., Grinkevich, Elizabeth, Reyes-Bricio, Estefanía, Kim, Choah, Clark, Abbe R., Watts, Andrew J.B., Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Luciene, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691435/
https://www.ncbi.nlm.nih.gov/pubmed/33294858
http://dx.doi.org/10.1016/j.xcrm.2020.100137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691435/
https://www.ncbi.nlm.nih.gov/pubmed/33294858
http://dx.doi.org/10.1016/j.xcrm.2020.100137

Ejemplares similares